virion
Newark, US · Founded 2018 · 2 known investors
Virion Therapeutics develops CD8+ T cell-based immunotherapies using genetically encoded checkpoint modifiers delivered with target-specific antigens via a viral vector platform, targeting cancers and chronic infectious diseases. Its lead product, VRON-0200, is in clinical development as a potential functional cure for chronic hepatitis B.
Founders & leadership
virion was founded in 2018 by Andrew Luber.
AL
Andrew LuberFounder
BR
Bernard RudnickNamed on SEC filing
Investors · 2
Competitors · 5
by search overlapAurion Biotech17 shared keywordsAurion Biotech develops regenerative cell therapies for ophthalmology, focused on treating blindness and vision loss from corneal endothelial disease. Its lead program, AURN001, is a combination therapy made from human donor endothelial cells intended to restore corneal clarity as an alternative to donor corneal transplantation.
Vividion Therapeutics15 shared keywordsVividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins. The company operates across the full drug development spectrum from discovery to clinical development.
Aro Biotherapeutics14 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Vivoryon13 shared keywordsVivoryon develops small molecule medicines targeting inflammatory and fibrotic kidney disorders, with a lead program (varoglutamstat) designed to treat diabetic kidney disease through protein modulation.
Veratx13 shared keywordsVera Therapeutics develops medicines targeting autoimmune-driven kidney diseases, with a focus on reducing the need for dialysis or transplant. The company was founded by a physician and operates as a clinical-stage biotech with a patient-centered approach to drug development.
Companies competing with virion for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements$10.9M disclosed across 2 rounds · 2018–2019
▶$5.7MraisedOct 2021 · 49 investors · BiotechnologyRule 506(b)
▶$5.7MraisedOct 2021 · 49 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andrew LuberExecutive Officer, Director
- Bernard RudnickExecutive Officer, Director
- Offering amount
- $6M
- Amount sold
- $5.7M
- Minimum investment
- $25K
- First sale
- Oct 2019
- Incorporated
- Limited Liability Company, Delaware, 2018
- Federal exemptions
- 06b
▶$5.2MraisedNov 2018 · 80 investors · BiotechnologyRule 506(b)
▶$5.2MraisedNov 2018 · 80 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bernard RudnickExecutive Officer, Director
- Andrew LuberExecutive Officer, Director
- Offering amount
- $5.5M
- Amount sold
- $5.2M
- Minimum investment
- $25K
- First sale
- Jun 2018
- Incorporated
- Limited Liability Company, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does virion do?
- Virion Therapeutics develops CD8+ T cell-based immunotherapies using genetically encoded checkpoint modifiers delivered with target-specific antigens via a viral vector platform, targeting cancers and chronic infectious diseases. Its lead product, VRON-0200, is in clinical development as a potential functional cure for chronic hepatitis B.
- Who founded virion?
- virion was founded by Andrew Luber in 2018.
- Who are virion's investors?
- virion's investors include Keiretsu Forum, Robin Hood Ventures.
- How much funding has virion raised?
- virion has disclosed $10.9M raised across 2 rounds.
- Where is virion headquartered?
- virion is headquartered in Newark, US.